Kevin G Phillips
Overview
Explore the profile of Kevin G Phillips including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
30
Citations
503
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Narayan V, Tholomier C, Mokkapati S, Martini A, Caruso V, Goudarzi M, et al.
Eur Urol Oncol
. 2024 Oct;
PMID: 39406613
Background And Objective: Urinary tumor DNA (utDNA) profiling identifies mutations associated with urothelial carcinoma and can be used to detect minimal residual disease (MRD). We evaluate the utility of utDNA...
2.
Rac G, Patel H, James C, Desai S, Caruso V, Fischer D, et al.
Mol Oncol
. 2023 Sep;
18(2):291-304.
PMID: 37753732
Intravesical therapy (IVT) is the standard of care to decrease risk of recurrence and progression for high-grade nonmuscle-invasive bladder cancer. However, post-IVT recurrence remains common and the ability to risk-stratify...
3.
Salari K, Sundi D, Lee J, Wu S, Wu C, DiFiore G, et al.
Clin Cancer Res
. 2023 Jul;
29(18):3668-3680.
PMID: 37439796
Purpose: Urinary comprehensive genomic profiling (uCGP) uses next-generation sequencing to identify mutations associated with urothelial carcinoma and has the potential to improve patient outcomes by noninvasively diagnosing disease, predicting grade...
4.
Bicocca V, Phillips K, Fischer D, Caruso V, Goudarzi M, Garcia-Ransom M, et al.
J Clin Med
. 2022 Oct;
11(19).
PMID: 36233691
The clinical standard of care for urothelial carcinoma (UC) relies on invasive procedures with suboptimal performance. To enhance UC treatment, we developed a urinary comprehensive genomic profiling (uCGP) test, UroAmplitude,...
5.
Assessment of the effects of Syk and BTK inhibitors on GPVI-mediated platelet signaling and function
Zheng T, Lofurno E, Melrose A, Lakshmanan H, Pang J, Phillips K, et al.
Am J Physiol Cell Physiol
. 2021 Mar;
320(5):C902-C915.
PMID: 33689480
Spleen tyrosine kinase (Syk) and Bruton's tyrosine kinase (BTK) play critical roles in platelet physiology, facilitating intracellular immunoreceptor tyrosine-based activation motif (ITAM)-mediated signaling downstream of platelet glycoprotein VI (GPVI) and...
6.
Healy L, Puy C, Itakura A, Chu T, Robinson D, Bylund A, et al.
J Immunol Methods
. 2016 Jun;
435:77-84.
PMID: 27286714
Background: Neutrophils, the most populous innate immune cell type, are the first responders to sites of infection and inflammation. Neutrophils can release their DNA to form extracellular traps (NETs), webs...
7.
Baker-Groberg S, Phillips K, Healy L, Itakura A, Porter J, Newton P, et al.
Cell Mol Bioeng
. 2015 Dec;
8(4):543-552.
PMID: 26640599
Physical theories of active matter continue to provide a quantitative understanding of dynamic cellular phenomena, including cell locomotion. Although various investigations of the rheology of cells have identified important viscoelastic...
8.
Baker-Groberg S, Bornstein S, Zilberman-Rudenko J, Schmidt M, Tormoen G, Kernan C, et al.
Cell Mol Bioeng
. 2015 Sep;
8(3):517-525.
PMID: 26417394
Head and neck squamous cell carcinoma (HNSCC) is the sixth leading cause of cancer worldwide. Although there are numerous treatment options for HNSCC, such as surgery, cytotoxic chemotherapy, molecularly targeted...
9.
King M, Phillips K, Mitrugno A, Lee T, de Guillebon A, Chandrasekaran S, et al.
Am J Physiol Cell Physiol
. 2015 Mar;
308(10):C792-802.
PMID: 25788574
Circulating tumor cells (CTC) have been implicated in the hematogenous spread of cancer. To investigate the fluid phase of cancer from a physical sciences perspective, the multi-institutional Physical Sciences-Oncology Center...
10.
Phillips K, Lee A, Tormoen G, Rigg R, Kolatkar A, Luttgen M, et al.
Am J Physiol Cell Physiol
. 2014 Nov;
308(3):C229-36.
PMID: 25411332
Thrombotic events can herald the diagnosis of cancer, preceding any cancer-related clinical symptoms. Patients with cancer are at a 4- to 7-fold increased risk of suffering from venous thromboembolism (VTE),...